Capricor to Release Q1 Results May 12, After Securing US-Japan Deramiocel Deal
CAPR•Capricor Therapeutics will release first-quarter 2026 results after market close on May 12 and host a conference call at 4:30 p.m. ET. The company secured exclusive commercialization rights for Deramiocel in the U.S. and Japan with Nippon Shinyaku, pending regulatory approval.
1. Q1 2026 Financial Results Release and Call
Capricor will report financial results for the quarter ended March 31, 2026, after market close on Tuesday, May 12. Management will host a live conference call and webcast at 4:30 p.m. ET, with toll-free dial-in at 1-800-717-1738, international access at 1-646-307-1865 (Conference ID: 60968), and a replay available on the company website.
2. Deramiocel Commercialization Agreement with Nippon Shinyaku
Capricor has entered an exclusive commercialization and distribution agreement for its lead product candidate, Deramiocel, in the U.S. and Japan with Nippon Shinyaku’s U.S. subsidiary, NS Pharma. This collaboration, subject to regulatory approvals, aims to advance Deramiocel in late-stage development for Duchenne muscular dystrophy and leverage the StealthX™ exosome platform across multiple therapeutic targets.
